ライフサイエンスコーパス: carboplatin

1 izable non-Pgp substrates (e.g. cisplatin or carboplatin).

2 ) polymerase (PARP) inhibitor, combined with carboplatin.

3 espond to Pt(II) drugs such as cisplatin and carboplatin.

4 g sensitivity of endometrial cancer cells to carboplatin.

5 ine for one course, with optional periocular carboplatin.

6 ing primary tumor response to paclitaxel and carboplatin.

7 eta3T negative, 47) received paclitaxel plus carboplatin.

8 e control arm, patients received gemcitabine/carboplatin.

9 y profile similar to that of the parent drug carboplatin.

10 and one patient had an allergic reaction to carboplatin.

11 rates without additive effects observed for carboplatin.

12 CIB2 also sensitized ovarian cancer cells to carboplatin.

13 rs and sensitized chemoresistant OC cells to carboplatin.

14 e one) or after cisplatin (400 mg/m(2)) plus carboplatin (1,700 mg/m(2); exposure two).

15 [66.7%]) was not increased further by adding carboplatin (17 of 26 [65.4%]).

16 ally higher with cisplatin (32.6%) than with carboplatin (18.7%).

17 Fluorinated carboplatin ((19)F-FCP) was synthesized using (19)F-labe

18 for delivery of melphalan 5 mg and possible carboplatin 30 mg.

19 SIOAC using either melphalan (5 mg/30 mL) or carboplatin (30 mg/30 mL).

20 ase, with additional topotecan (1 mg) and/or carboplatin (30 or 50 mg) as necessary.

21 ificantly increased pCR breast, whereas only carboplatin (54% v 41%; P = .0029) significantly raised

22 oying one-sided P values, addition of either carboplatin (60% v 44%; P = .0018) or bevacizumab (59% v

23 eceived his first of two cycles of high-dose carboplatin 700 mg/m(2) on days -5, -4, and -3 and etopo

24 al rates when carboplatin was added (without carboplatin, 73.5%; 95% CI, 64.1%-80.8% vs with carbopla

25 boplatin, 73.5%; 95% CI, 64.1%-80.8% vs with carboplatin, 85.3%; 95% CI, 77.0%-90.8%; hazard ratio, 0

26 ta3T negative, 43) received ixabepilone plus carboplatin; 96 patients (beta3T positive, 49; beta3T ne

27 the present pharmaceutical options, such as carboplatin a metallodrug based on Pt coordination chemi

28 cess used in our trial showed that veliparib-carboplatin added to standard therapy resulted in higher

29 Following IVC (vincristine, etoposide, and carboplatin), adjuvant treatments included intraophthalm

30 ree survival as compared with paclitaxel and carboplatin administered every 3 weeks among patients re

31 he addition of bevacizumab to paclitaxel and carboplatin administered every 3 weeks has shown efficac

32 Carboplatin administered systemically or periocularly ca

33 ed an acute decrease in expression 4 h after carboplatin administration that recovered within 48 h in

34 horoids and lenses showed very low levels of carboplatin after 6 hours, with negligible amounts at 72

35 ximab and 16% (four of 25) to cetuximab plus carboplatin after progression.

36 latinum-sensitive A459 cells and higher than carboplatin against platinum-resistant SK-OV-3 cells.

37 ctivity of an untagged analog was similar to carboplatin against platinum-sensitive A459 cells and hi

38 ) or nivolumab 5 or 10 mg/kg plus paclitaxel-carboplatin (all histologies).

39 ression-free survival versus paclitaxel plus carboplatin alone, with the greatest clinical benefit in

40 with a 5-drug combination of vincristine and carboplatin, alternating with cyclophosphamide, idarubic

41 latinated pro-drug possessing 11 copies of a carboplatin analogue conjugated to the B12(2-) core via

42 ve courses of HDCT consisting of 700 mg/m(2) carboplatin and 750 mg/m(2) etoposide, each for 3 consec

43 PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous

44 for CA125-negative cells, co-treatment with carboplatin and birinapant eliminates these cells in HGS

45 e safety and efficacy of HDCT, consisting of carboplatin and etoposide followed by stem cell reinfusi

46 efficacy of the addition of palifosfamide to carboplatin and etoposide in extensive stage (ES) small-

47 ncers preferentially survived treatment with carboplatin and etoposide in vitro and in human MCC xeno

48 (VEC) and group B patients were treated with carboplatin and etoposide, alternating with cyclophospha

49 and after bevacizumab plus chemotherapy with carboplatin and nab-paclitaxel in advanced NSCLC patient

50 ter randomized phase II neoadjuvant trial of carboplatin and nanoparticle albumin-bound paclitaxel (C

51 The pCR rates between the carboplatin and noncarboplatin arms were compared.

52 Cisplatin and its platinum analogs, carboplatin and oxaliplatin, are some of the most widely

53 improve overall survival (OS) compared with carboplatin and paclitaxel (CP) in chemotherapy-naive pa

54 We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of adva

55 s the effect of the addition of cediranib to carboplatin and paclitaxel chemotherapy in patients with

56 ranib has significant efficacy when added to carboplatin and paclitaxel in the treatment of metastati

57 ter, who underwent nCRT (5 weekly courses of carboplatin and paclitaxel plus 41.4 Gy concurrent radio

58 nts receiving adjuvant first-line therapy of carboplatin and paclitaxel with curative intent.

59 patients received concurrent chemotherapy of carboplatin and paclitaxel with or without cetuximab, an

60 trexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite

61 ed the effects of the chemotherapeutic drugs carboplatin and PX-866 to reduce proliferation and survi

62 ine mutations benefited from the addition of carboplatin and those with BRCA1 and BRCA2 mutations sho

63 owed by three alternating administrations of carboplatin and vincristine for two courses and topoteca

64 ase II trial, evaluated the impact of adding carboplatin and/or bevacizumab.

65 were randomly assigned to receive veliparib-carboplatin, and 44 patients were concurrently assigned

66 agents (mitomycin C, oxaliplatin, cisplatin, carboplatin, and a PARP inhibitor) results in HuR's tran

67 clusion Topotecan combined with vincristine, carboplatin, and aggressive focal therapies is an effect

68 -dose chemotherapy and concurrent periocular carboplatin, and EBRT selectively in chemotherapy failur

69 ximab vedotin (BV) and augmented ifosfamide, carboplatin, and etoposide (augICE), we assessed clinica

70 tinum-based chemotherapy, either ifosfamide, carboplatin, and etoposide (ICE) or dexamethasone, cytar

71 b vedotin, followed by augmented ifosfamide, carboplatin, and etoposide (ICE).

72 plus cisplatin, 18 received pemetrexed plus carboplatin, and four received a combination.

73 showed significant benefit for gemcitabine, carboplatin, and iniparib (GCI) over gemcitabine and car

74 Preoperative combination of gemcitabine, carboplatin, and iniparib is active in the treatment of

75 isplatin, nivolumab 10 mg/kg plus paclitaxel-carboplatin, and nivolumab 5 mg/kg plus paclitaxel-carbo

76 The platinum drugs cisplatin, carboplatin, and oxaliplatin are highly utilized in the

77 platinum-based anticancer agents cisplatin, carboplatin, and oxaliplatin represent a spectacular tra

78 Platinum-based drugs (cisplatin, carboplatin, and oxaliplatin) are widely used therapeuti

79 on platinum complexes, including cisplatin, carboplatin, and oxaliplatin, finding that DMSO reacted

80 The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment o

81 Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and to

82 toxicity assessment, RR in cisplatin versus carboplatin, and RR in molecularly defined subgroups, in

83 taxel, and trastuzumab (ACTH) and docetaxel, carboplatin, and trastuzumab (TCH).

84 etaxel and cyclophosphamide (TC); docetaxel, carboplatin, and trastuzumab (TCH); or doxorubicin and c

85 concurrently with trastuzumab or docetaxel, carboplatin, and trastuzumab for six cycles are recommen

86 ose, 420 mg maintenance doses) or docetaxel, carboplatin, and trastuzumab plus pertuzumab (docetaxel

87 ansine plus pertuzumab (n=223) or docetaxel, carboplatin, and trastuzumab plus pertuzumab (n=221).

88 23 (55.7%) of 221 patients in the docetaxel, carboplatin, and trastuzumab plus pertuzumab group (abso

89 n grade 3-4 adverse events in the docetaxel, carboplatin, and trastuzumab plus pertuzumab group were

90 plus dual HER2-targeted blockade (docetaxel, carboplatin, and trastuzumab plus pertuzumab) resulted i

91 3 patients vs 11 [5%] of 219 with docetaxel, carboplatin, and trastuzumab plus pertuzumab), fatigue (

92 compared with patients receiving docetaxel, carboplatin, and trastuzumab plus pertuzumab, fewer pati

93 umab emtansine plus pertuzumab or docetaxel, carboplatin, and trastuzumab plus pertuzumab.

94 so exhibited enhanced ABCB5 positivity after carboplatin- and etoposide-based chemotherapy, pointing

95 Carboplatin- and etoposide-resistant MCC cell lines exhi

96 Although cisplatin and carboplatin are used primarily in germ cell, breast and

97 e platinum chemotherapy agents cisplatin and carboplatin are widely used in the treatment of adult an

98 tem to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetre

99 zumab plus pertuzumab (docetaxel 75 mg/m(2); carboplatin area under the concentration-time curve 6 mg

100 1 receptor antagonist for adults who receive carboplatin area under the curve >/= 4 mg/mL per minute

101 y allocated to gemcitabine 1,000 mg/m(2) and carboplatin area under the curve 2 (days 1 and 8) alone

102 m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg

103 eeks or paclitaxel 175 mg/m(2) combined with carboplatin area under the curve 6 every 3 weeks) until

104 ; dacarbazine 1,000 mg/m(2) every 3 weeks or carboplatin area under the curve 6 plus paclitaxel 175 m

105 latin 50 mg/m(2) and four adjuvant cycles of carboplatin area under the curve [AUC] 5 and paclitaxel

106 before chemotherapy (cisplatin 80 mg/m(2) or carboplatin area under the curve of 5 on day 1 plus etop

107 1:1 to receive ixabepilone (32 mg/m(2)) and carboplatin (area under concentration-time curve [AUC],

108 es, and were randomly assigned to concurrent carboplatin (area under curve 6) once every 3 weeks for

109 mg/m(2) intravenously [IV] on days 1 and 8), carboplatin (area under curve of 2 IV on days 1 and 8),

110 standard chemotherapy (total 18 weeks) with carboplatin (area under the curve 5 or 6) and paclitaxel

111 C were randomly assigned to 3-week cycles of carboplatin (area under the curve 6) and paclitaxel (200

112 2), administered intravenously on day 1) and carboplatin (area under the curve [AUC] 4 mg/mL per min,

113 e randomly assigned to 12 wk of preoperative carboplatin (area under the curve of 2, weekly) and nab-

114 paclitaxel (200 mg/m(2); every 21 days) plus carboplatin (area under the curve of 6 by modified Calve

115 ients and Methods Patients were treated with carboplatin (area under the curve, 5 mg/mLmin) combined

116 taxel [175 mg/m(2) of body surface area] and carboplatin [area under the curve 5]) or the same chemot

117 RCA1 and BRCA2 mutations achieved pCR in the carboplatin arm vs 44 of the 121 patients (36.4%) in the

118 eceive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B).

119 a and thrombocytopenia were more common with carboplatin, as were hypertension, infection, thromboemb

120 emcitabine 1,000 mg/m(2) on days 1 and 8 and carboplatin at area under the [concentration-time] curve

121 andomly assigned in a 1:1 fashion to receive carboplatin at area under the serum concentration-time c

122 per day on days 1 to 3 every 21 days (CE) or carboplatin at area under the serum concentration-time c

123 t cell lines and compared with cisplatin and carboplatin at different concentrations.

124 nfusion over 24 h, days 1 and 2; one dose of carboplatin AUC 5, day 3; three doses of etoposide 200 m

125 based chemotherapy ([cisplatin 75 mg/m(2) or carboplatin AUC 5-6 plus pemetrexed 500 mg/m(2)] every 3

126 , 4.7 to 7.8 months); PFS was greater in the carboplatin AUC 5.0 group (P = .04).

127 Eligible patients received carboplatin AUC of 5 plus paclitaxel 175 mg/m(2) by infu

128 p), or paclitaxel (175 mg/m(2) on day 1) and carboplatin (AUC 6 mg/mL per min on day 1) then no furth

129 n consisting of paclitaxel (200 mg/m(2)) and carboplatin (AUC 6).

130 ly at a dose of 80 mg per square meter, plus carboplatin (AUC, 6) for six cycles.

131 ve [AUC], 6) or paclitaxel (200 mg/m(2)) and carboplatin (AUC, 6) for up to six cycles.

132 otherapy (six 3-weekly cycles of intravenous carboplatin [AUC 5 or 6] and paclitaxel 175 mg/m(2) of b

133 eceived DD chemotherapy consisting of weekly carboplatin (AUC2) and paclitaxel (60-80 mg/m(2)) as the

134 Each 3-week cycle consisted of carboplatin AUC5 or AUC6 plus paclitaxel 175 mg/m(2), or

135 Addition of carboplatin, B, or both increased conversion rates.

136 Since treatment efficacy of cisplatin- or carboplatin-based chemotherapy in the first-line treatme

137 Standard front-line treatment using carboplatin-based chemotherapy typically produces only a

138 ent allocation on the basis of CGA (CGA arm: carboplatin-based doublet for fit patients, docetaxel fo

139 on on the basis of PS and age (standard arm: carboplatin-based doublet if PS </= 1 and age </= 75 yea

140 arms, 35.1% and 45.7% of patients received a carboplatin-based doublet, 64.9% and 31.3% received doce

141 is therapy sensitized breast cancer cells to carboplatin-based therapy and increased host survival.

142 rom 185 patients who relapsed after adjuvant carboplatin between January 1987 and August 2013 at 31 c

143 actorial trial of neoadjuvant paclitaxel +/- carboplatin +/- bevacizumab (B) followed by doxorubicin

144 He was briefly treated with gemcitabine and carboplatin, but this was discontinued as a result of ra

145 irinapant sensitizes CA125-negative cells to carboplatin by mediating degradation of cIAP causing cle

146 lls treated with doxorubicin, paclitaxel, or carboplatin by suppressing apoptosis and upregulating NF

147 cizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevac

148 efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemet

149 rular filtration rate (GFR) is essential for carboplatin chemotherapy dosing; however, the best metho

150 are deadly malignancies that relapse despite carboplatin chemotherapy.

151 and its expression increases in response to carboplatin chemotherapy.

152 t to chemotherapeutic agents (5-fluoruracil, carboplatin, cisplatin, eribulin, and paclitaxel), based

153 us paclitaxel 175 mg/m(2), or an alternative carboplatin combination regimen, or carboplatin monother

154 forin, and IFN-gamma, we therefore evaluated carboplatin combination therapy resulting in a significa

155 ted of five weekly courses of paclitaxel and carboplatin combined with a concurrent radiation dose of

156 ring loss included exposure to cisplatin and carboplatin compared with cisplatin alone and hospitaliz

157 toposide, and melphalan regimen consisted of carboplatin continuous infusion of area under the plasma

158 in this setting is unlikely, but the role of carboplatin could be evaluated in definitive studies, id

159 ed a multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposid

160 py (paclitaxel plus carboplatin, paclitaxel, carboplatin, dacarbazine, or oral temozolomide).

161 aminedichloroplatinum II (cDDP, cis-platin), carboplatin, dacarbazine, or temozolomide together with

162 (gemcitabine at 1000 mg/m2 Days 1 and 8 with carboplatin delivered according to an area-under-the-cur

163 Results AZD1775 plus carboplatin demonstrated manageable toxicity; fatigue (8

164 olerated dose of AZD1775 in combination with carboplatin demonstrated target engagement.

165 rting on the development of an (18)F-labeled carboplatin derivative ((18)F-FCP) that has the potentia

166 This strategy of using a new therapeutic carboplatin derivative to quantify and track platinum dr

167 larly, adding a third drug to etoposide with carboplatin does not seem to substantially improve treat

168 show that oxaliplatin, unlike cisplatin and carboplatin, does not kill cells through the DNA-damage

169 odel reduced the fraction of patients with a carboplatin dose absolute percentage error > 20% to 14.1

170 ter of body-surface area every 3 weeks, plus carboplatin (dose equivalent to an area under the curve

171 We performed a comparison of carboplatin dosing accuracy on the basis of an absolute

172 rapy-induced overactivation, mice were given carboplatin, doxorubicin, or cyclophosphamide and were c

173 oviding clinical proof that AZD1775 enhances carboplatin efficacy in TP53-mutated tumors.

174 While treatment with carboplatin enriches for CA125-negative cells, co-treatm

175 ed to six cycles of chemotherapy (paclitaxel/carboplatin +/- enzastaurin [PCE/PC]) followed by mainte

176 sulfan and melphalan and at least 72 h after carboplatin etoposide, and melphalan.

177 ne) followed by 3 cycles of ICE (ifosfamide, carboplatin, etoposide).

178 signed (1:1) to busulfan and melphalan or to carboplatin, etoposide, and melphalan by minimisation, b

179 an and melphalan group and 188 of 302 in the carboplatin, etoposide, and melphalan group had an event

180 e busulfan and melphalan group and 11 in the carboplatin, etoposide, and melphalan group had died wit

181 d melphalan group vs 103 [38%] of 270 in the carboplatin, etoposide, and melphalan group), infection

182 clusive disease versus 21 (9%) of 239 in the carboplatin, etoposide, and melphalan group.

183 The carboplatin, etoposide, and melphalan regimen consisted

184 ed: 296 to busulfan and melphalan and 302 to carboplatin, etoposide, and melphalan.

185 lfan and melphalan and 29 (10%) who received carboplatin, etoposide, and melphalan.

186 caused fewer severe adverse events than did carboplatin, etoposide, and melphalan.

187 py with busulfan and melphalan compared with carboplatin, etoposide, and melphalan.

188 n a greater frequency of drug delivery) plus carboplatin every 3 weeks or the addition of bevacizumab

189 to six cycles of etoposide plus cisplatin or carboplatin every 3 weeks, until disease progression or

190 Olaparib plus paclitaxel and carboplatin followed by maintenance monotherapy signific

191 demonstrate that repeated administration of carboplatin followed by T4(+) T cells achieved optimum t

192 ommonly treated with adjuvant doxorubicin or carboplatin following amputation of the affected limb.

193 ents who experience a relapse after adjuvant carboplatin for clinical stage I seminoma can be success

194 tin, and iniparib (GCI) over gemcitabine and carboplatin (GC) in clinical benefit rate, response rate

195 domly assigned to receive either gemcitabine/carboplatin (GC) or methotrexate/carboplatin/vinblastine

196 Although gemcitabine and carboplatin (GCa) is a standard option for patients with

197 liplatin (GEMOX) combination and Gemcitabine/Carboplatin (Gem/Carb) combination regimens have shown e

198 y interval [PI], 36 to 66%) in the veliparib-carboplatin group versus 26% (95% PI, 9 to 43%) in the c

199 ly for the nivolumab 5 mg/kg plus paclitaxel-carboplatin group, with a 2-year OS rate of 62%.

200 etinoblastoma who were treated with systemic carboplatin had a higher incidence of ototoxicity than p

201 to triple-negative breast cancer, veliparib-carboplatin had an 88% predicted probability of success

202 apy with vincristine sulfate, etoposide, and carboplatin had failed in 10 patients (91%) and 6 eyes (

203 rimental arm, which consisted of gemcitabine/carboplatin if RRM1 and ERCC1 were low, docetaxel/carbop

204 platin if RRM1 and ERCC1 were low, docetaxel/carboplatin if RRM1 was high and ERCC1 was low, gemcitab

205 Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports addit

206 olvent-based paclitaxel (sb-paclitaxel) plus carboplatin in advanced non-small-cell lung cancer (NSCL

207 iniparib in combination with gemcitabine and carboplatin in early-stage triple-negative and BRCA1/2 m

208 s seeds and additional concurrent periocular carboplatin in patients with diffuse vitreous seeds.

209 a combination of vincristine, etoposide, and carboplatin in patients with focal vitreous seeds and ad

210 posterior subtenon injection of nanoparticle carboplatin in the eye to be enucleated.

211 In contrast, carboplatin increased response rates in patients without

212 Treatment with cisplatin or carboplatin increased the potency of tumor cell lines to

213 with the FDA-approved chemotherapeutic agent carboplatin induced autophagy and growth inhibition, whi

214 ment strategy for patients with a history of carboplatin-induced HSRs with negative carboplatin ST re

215 These patients might be at risk for future carboplatin-induced HSRs.

216 Maintenance treatment with SGI-110 after carboplatin inhibited OCSC growth, causing global tumor

217 s seeds received a 15-mg posterior sub-Tenon carboplatin injection (range, 1-13 mg; median, 6 mg).

218 Purpose Adjuvant carboplatin is one of three management strategies that m

219 The best carboplatin model utilized canine lines for gene identif

220 ernative carboplatin combination regimen, or carboplatin monotherapy.

221 line therapy) received cisplatin (n = 43) or carboplatin (n = 43).

222 n combination with the standard-of-care drug carboplatin, ND-646 markedly suppressed lung tumor growt

223 We investigated the impact of cisplatin and carboplatin on 10 different cervical and ovarian cancer

224 The effects of carboplatin on mesothelial VCAM-1 expression were determ

225 chemotherapy with 45 mg/m(2) paclitaxel and carboplatin once a week (AUC 2); 2 weeks after chemoradi

226 In stage II to III TNBC, addition of either carboplatin or bevacizumab to NACT increased pCR rates,

227 Patients assigned to either carboplatin or bevacizumab were less likely to complete

228 t chemoradiotherapy with either docetaxel or carboplatin or concurrent chemoradiotherapy alone with t

229 SC enrichment, in response to treatment with carboplatin or doxorubicin.

230 Reducing cisplatin and high-dose carboplatin ototoxicity without reducing efficacy is imp

231 ctive of this study was to determine whether carboplatin, paclitaxel, and sorafenib (CPS) improve ove

232 tigator-choice chemotherapy (paclitaxel plus carboplatin, paclitaxel, carboplatin, dacarbazine, or or

233 several antineoplastic agents (oxaliplatin, carboplatin, paclitaxel, docetaxel, cyclophosphamide, an

234 sponse rates between cisplatin-etoposide and carboplatin-paclitaxel (58% vs 56%; P = .26), respective

235 tion with either etoposide-cisplatin (EP) or carboplatin-paclitaxel (CP).

236 4 hematological toxic effects compared with carboplatin-paclitaxel (eg, neutropenia [54% vs 23%; P <

237 at the end of the second week of first cycle carboplatin-paclitaxel and bevacizumab (CPB) treatment.

238 IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide.

239 .0 Gy), and 3728 patients from 48 studies in carboplatin-paclitaxel groups (median age, 63 years; 65%

240 oxic effects between cisplatin-etoposide and carboplatin-paclitaxel in patients with non-small-cell l

241 III disease receiving radiotherapy (RT) with carboplatin-paclitaxel or cisplatin-etoposide were ident

242 The toxic effect profiles favored the carboplatin-paclitaxel regimen.

243 Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with com

244 The associations between carboplatin-paclitaxel with vs without bevacizumab and o

245 Concurrent chemotherapy (carboplatin-paclitaxel) and passively scattered PBT (74-

246 For cisplatin-etoposide vs carboplatin-paclitaxel, there was no significant differe

247 poside (C/E, n = 28) weeks 1 and 5 or weekly carboplatin/paclitaxel (C/P, n = 32) regimens.

248 nd safety of enzastaurin added to a standard carboplatin/paclitaxel chemotherapy regimen in patients

249 ions (CI=0.4-0.82) vs. an additive effect in carboplatin/paclitaxel treatment (CI=1.5-2).

250 s 60-Gy RT with concurrent and consolidation carboplatin/paclitaxel with or without cetuximab.

251 All patients were treated with nCRT (carboplatin/paclitaxel/41.4 Gy) followed by esophagectom

252 in plus pemetrexed for nonsquamous NSCLC and carboplatin plus gemcitabine for squamous histology.

253 modified Calvert formula; every 21 days) or carboplatin plus paclitaxel and bevacizumab (15 mg/kg; e

254 /QALY, and first-line NIVO + IPI followed by carboplatin plus paclitaxel chemotherapy produced an inc

255 ally fit patients received concurrent weekly carboplatin plus paclitaxel followed by 3 cycles of cons

256 with PS 0 to 1 (bevacizumab may be added to carboplatin plus paclitaxel if no contraindications); co

257 ods Patients were randomly assigned to nCRT (carboplatin plus paclitaxel with concurrent 41.4-Gy radi

258 t in PFS with the addition of bevacizumab to carboplatin plus paclitaxel.

259 Chemotherapy was determined by histology: carboplatin plus pemetrexed for nonsquamous NSCLC and ca

260 Treatment with carboplatin plus pemetrexed was initiated, without bevac

261 Veliparib-carboplatin plus standard therapy was considered for HER

262 atinum-resistant ovarian cancer who received carboplatin plus the DNA methyltransferase inhibitor gua

263 sion and chemosensitivity to paclitaxel plus carboplatin (PTX/CBP) regimen, an effective neoadjuvant

264 The concentration of carboplatin reaching various intraocular tissues was det

265 ain a CA125-negative population enriched for carboplatin-resistant cancer initiating cells.

266 er kilogram of body weight of paclitaxel and carboplatin, respectively (P < .001 for each agent).

267 eatment of mesothelial cells in culture with carboplatin resulted in a transient decrease in VCAM-1 e

268 ur results demonstrated that (19)F-FCP, like carboplatin, retains antitumor activity in various cell

269 lobe-sparing therapies, including periocular carboplatin, selective ophthalmic artery chemoreduction,

270 , prior treatment with noncytotoxic doses of carboplatin sensitized SKOV-3 tumors to T4 immunotherapy

271 ure to cisplatin combined with myeloablative carboplatin significantly increases risk.

272 ry of carboplatin-induced HSRs with negative carboplatin ST results.

273 chemotherapy with 175 mg/m(2) paclitaxel and carboplatin (target area under the curve of 6) given 21

274 antly longer treatment-response durations to carboplatin than did men without defects in genes encodi

275 DT and the standard-of-care chemotherapeutic carboplatin that evolved over time.

276 icantly increased the anti-tumor efficacy of carboplatin, the chemotherapy most commonly used to trea

277 ed evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, ta

278 aimed to assess the efficacy and toxicity of carboplatin +/- topotecan delivered by ophthalmic artery

279 57 carboplatin +/- topotecan infusions (of 111 total) were

280 Carboplatin +/- topotecan infusions are effective for op

281 igated retinoblastoma patients whom received carboplatin +/- topotecan ophthalmic artery chemosurgery

282 variate analysis, neither increasing maximum carboplatin/topotecan dose nor cumulative carboplatin/to

283 um carboplatin/topotecan dose nor cumulative carboplatin/topotecan dose was associated with statistic

284 ecurrent ovarian carcinomas after paclitaxel/carboplatin treatment have higher levels of spleen tyros

285 Specifically, carboplatin treatment of mice with platinum-sensitive tu

286 ith or without single intravenous paclitaxel/carboplatin treatment.

287 Patients received cisplatin (two trials) or carboplatin (two trials).

288 ere treated with vincristine, etoposide, and carboplatin (VEC) and group B patients were treated with

289 ncristine sulphate, etoposide phosphate, and carboplatin (VEC).

290 gemcitabine/carboplatin (GC) or methotrexate/carboplatin/vinblastine (M-CAVI).

291 leted treatment with multiagent chemotherapy-carboplatin, vincristine, temozolomide, procarbazine, lo

292 ed elevated disease-free survival rates when carboplatin was added (without carboplatin, 73.5%; 95% C

293 The highest level of carboplatin was detected in retinas (8.33 +/- 1.69 mg/g)

294 The toxicity of veliparib-carboplatin was greater than that of the control.

295 The distribution of cisplatin and carboplatin was mapped in additional 3D tumor mimics.

296 use of the recent transient ischemic attack; carboplatin was selected over cisplatin because of simil

297 Intravenous concentration of carboplatin was undetectable in all patients.

298 latin, and nivolumab 5 mg/kg plus paclitaxel-carboplatin were 33%, 47%, 47%, and 43%, respectively; 2

299 bumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel

300 ated trans-scleral transport of nanoparticle carboplatin, with a sustained-release behavior but witho

301 ine whether dose-dense weekly paclitaxel and carboplatin would prolong progression-free survival as c